A multicenter, register-based, randomized, controlled trial comparing dapagliflozin with metformin treatment in early stage type 2 diabetes patients by assessing mortality and macro- and microvascular complications
This important study is looking at two established treatments for type 2 diabetes: dapagliflozin and metformin. We are trying to understand which of these medicines might be better for people who have recently been diagnosed with type 2 diabetes. The main goal is to see if one medicine helps prevent serious health problems like heart attacks, strokes, heart failure, and kidney or eye damage more effectively than the other. We're also checking how these medicines affect blood sugar, cholesterol, blood pressure, and overall quality of life. This research will help doctors know the best way to start treating people with type 2 diabetes to keep them as healthy as possible for longer.
At a glance
What is this study about?
Imagine you've just been diagnosed with type 2 diabetes. Your doctor will talk to you about different treatments. One common medicine is metformin, which has been used for a long time. Another medicine, called dapagliflozin, is also used and works in a slightly different way to help manage blood sugar.
This study is designed to compare these two medicines in people who are in the early stages of type 2 diabetes. We want to find out if one of them is better at preventing serious health issues that can happen with diabetes over time. These issues include problems with the heart, like heart attacks, strokes, or heart failure, as well as problems with the eyes (retinopathy), kidneys (nephropathy), and feet (diabetic foot lesions). By carefully comparing dapagliflozin and metformin, we hope to learn which medicine helps people stay healthier for longer.
This research is important because it will give doctors clearer information to help them choose the best starting treatment for someone newly diagnosed with type 2 diabetes. Improving these choices could lead to fewer serious complications for people living with diabetes, helping them to live fuller, healthier lives.
Key takeaways
- Compares two common diabetes medicines: dapagliflozin and metformin.
- Focuses on people recently diagnosed with type 2 diabetes.
- Aims to prevent serious health issues like heart attacks, strokes, and kidney problems.
- Uses routine medical records, so no extra appointments for participants.
- Results will help doctors choose the best initial treatment for type 2 diabetes.
- Open to adults aged 18 and over, both men and women.
Who may be eligible?
To be able to join this study, you would need to be an adult, 18 years old or older. Both men and women can take part.
The study is specifically looking for people who are in the early stages of type 2 diabetes. This means you would have received a diagnosis of type 2 diabetes relatively recently. The study will also be looking at detailed information from your medical records to make sure it's safe and appropriate for you to participate.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with type 2 diabetes?
- Are you willing to have your health information collected from your medical records?
- Are you able to take either dapagliflozin or metformin?
- Have you discussed your participation with your doctor?
What does participation involve?
If you decide to take part in this study, you would be randomly assigned to receive either dapagliflozin or metformin. This is like flipping a coin, so neither you nor your doctor can choose which medication you receive. You would take your assigned medication as prescribed.
Throughout the study, information about your health will be collected from your existing medical records. This includes details of any medical appointments you have, test results (like blood sugar, cholesterol, and blood pressure), and if you develop any health problems. There are no extra hospital visits or special appointments just for the study; all the information is gathered from your routine healthcare. The study will follow people for a number of years to see the long-term effects of the medications.
Potential risks and benefits
Locations (1)
- —UnverifiedSweden
Common questions
What's the main point of this study?
It's comparing two diabetes medicines (dapagliflozin and metformin) to see which is better at preventing serious health problems in people newly diagnosed with type 2 diabetes.
Will I have extra doctor's appointments if I join?
No, this study mainly collects information from your existing medical records, so you won't have extra visits just for the study.
Who can take part in this study?
Adults aged 18 and over, both men and women, who have been diagnosed with type 2 diabetes relatively recently.
What kind of health problems are they looking for?
They're looking at things like heart attacks, strokes, heart failure, and problems with your eyes, kidneys, and feet.
Can I choose which medicine I get?
No, you will be randomly assigned to either dapagliflozin or metformin, like drawing lots or flipping a coin.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.